Johannes Bigenzahn

152 posts

Johannes Bigenzahn

Johannes Bigenzahn

@bigenzahn

شامل ہوئے Mayıs 2016
571 فالونگ191 فالوورز
Johannes Bigenzahn ری ٹویٹ کیا
NEJM
NEJM@NEJM·
Original Article: Asciminib in Newly Diagnosed Chronic Myeloid Leukemia (ASC4FIRST): nej.md/4bNNr3c Editorial: CML 25 Years Later — Poised for Another Breakthrough? nej.md/3MAHbkO #Oncology
NEJM tweet media
English
1
13
35
14.9K
Johannes Bigenzahn
Johannes Bigenzahn@bigenzahn·
Happy to see this project being published 🎉🥂thank you to everybody involved ! I’m very much looking forward to future applications of our LZTR1 screening assay and potential novel discoveries 🤞🤞🤞
Superti-Furga Lab@gsf_lab

News from our research line on signaling in cancer: We found a new fragment engaging RAS which is capable of inducing association with LZTR1: Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3LZTR1 E3 Ligase KRAS Complex pubs.acs.org/doi/10.1021/ac…

English
1
1
16
714
Johannes Bigenzahn ری ٹویٹ کیا
Michael Makris
Michael Makris@ProfMakris·
Intresting short article in @NatureMedicine discussing the decline in clinical academics in the UK and US. Another issue, not discussed, is the failure to recognise all the components of the job equally, clinical/research/teaching. The interests of Universities and the NHS are not the same and clinical academics suffer as a result. @StephenORahilly
Michael Makris tweet media
English
14
158
337
123.4K
Johannes Bigenzahn ری ٹویٹ کیا
Neville Sanjana
Neville Sanjana@nevillesanjana·
Happy 10th birthday to CRISPR pooled screens! 🎂🎂🎂🎂🎂🎂🎂🎂🎂🎂
English
2
14
171
23.8K
Johannes Bigenzahn ری ٹویٹ کیا
Patrizia Mondello, MD, PhD, MSc
Patrizia Mondello, MD, PhD, MSc@pattymondello·
Physician Scientists have dropped from 4.5% to 1.5% today. Main causes: fundings, clinical demands, disparities in salaries between research track physician scientists and full-time clinicians, inequitable support for women and minorities jamanetwork.com/journals/jaman…
English
4
176
388
117.7K
Johannes Bigenzahn ری ٹویٹ کیا
Florian Klenk
Florian Klenk@florianklenk·
Schwarz-Grün hat also tatsächlich eine angesehene Qualitätszeitung ermordet. Und daraus eine Contentfabrik für Regierungspropaganda gemacht. Zugleich haben wir Gesetze, die dem ÖVP-nahen Putin-Exxpress eine Million zuschanzen. Es ist eine Kulturschande.
Simon Rosner 📰@SimonRosner

Hier ist sie, die letzte. Die Allerletzte.

Deutsch
63
202
1.4K
126.7K
Johannes Bigenzahn ری ٹویٹ کیا
tagesthemen
tagesthemen@tagesthemen·
„Was da in der Nacht des 14. Juni vor Griechenlands Küste geschah, ist kein Drama, keine Tragödie, keine Katastrophe. Es ist ein Verbrechen. Und zwar eines, an dem gleich mehrere Täter beteiligt sind.“ Die #Meinung von @georgrestle vom @wdr (red)
Deutsch
688
634
2.6K
541.6K
Johannes Bigenzahn ری ٹویٹ کیا
Maarten Larmuseau
Maarten Larmuseau@MHDLarmuseau·
Today we finally published the genomic analyses of hair locks from world-famous music composer Ludwig van #Beethoven. The #genome offers clues to his health and family history! 🧬💇‍♂️ @CurrentBiology buff.ly/3YZEVY0 (credits: Beethoven-Haus Bonn; T. Begg) 🧵 1/11
Maarten Larmuseau tweet media
English
46
487
1.6K
500.6K
Johannes Bigenzahn ری ٹویٹ کیا
Neville Sanjana
Neville Sanjana@nevillesanjana·
Delighted to see this CRISPR screen collab w/ @WeiWei29206770 & @DrBenNeel out today. And congrats to @CathyxGuo from our lab who contributed to the study! Tremendous clinical potential for SHP2 inhibitors and hence impt to understand potential resistance mechanisms.💊✂️🧬👨‍🔬
Rockefeller U. Press@RockUPress

In @JExpMed, Wei Wei, @DrBenNeel et al @nyulangone perform CRISPR/Cas9 screens for SHP2 inhibitor resistance. Deletion of resistance genes causes ERK activation & cross-resistance to FLT3-ITD/BCR-ABL inhibition in FLT3-ITD or BCR-ABL–driven AML lines. bit.ly/3ZiNtto

English
1
3
22
5.4K
Johannes Bigenzahn ری ٹویٹ کیا
Jay Bradner, M.D.
Jay Bradner, M.D.@jaybradner·
Great paper from @DrBenNeel dissecting and anticipating KO resistance mechanisms to SHP2 inhibition (where SA activity apparent). LZTR1 for the win, with some new proteins to dig into. Hopeful for ORFeome screen to follow, suspect will more map downstream.
English
1
2
21
11.7K
Johannes Bigenzahn ری ٹویٹ کیا
Cancer Discovery
Cancer Discovery@CD_AACR·
Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. bit.ly/3GkSqZK @Ludwig_Cancer
Cancer Discovery tweet media
English
20
784
1.8K
0
Johannes Bigenzahn ری ٹویٹ کیا
Tea Pemovska, PhD
Tea Pemovska, PhD@TPemovska·
Very honored to share our newest paper on targeting cancer cell metabolism in myeloid leukemias out today in Nature Communications. Thanks to all the collaborators and funders. Particularly @giuliosf, @bigenzahn, @gsf_lab & StaberLab. Conducted @CeMM_News & @MedUni_Wien.
CeMM@CeMM_News

The study “Metabolic drug survey highlights cancer cell dependencies and vulnerabilities” was published in the journal @NatureComms on 14 December 2021. nature.com/articles/s4146…

English
5
3
29
0